Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a significant global health challenge, with limited treatment options for advanced disease.
• Single-cell transcriptomics reveals TGF-β signaling's role in HNSCC invasiveness, treatment resistance, and immune evasion.
• TGF-β signaling mediates interactions between cancer-associated fibroblasts and mesenchymal cancer cells.

Purpose of the Study:

• To critically review preclinical and clinical findings of TGF-β inhibitors in HNSCC.
• To explore the potential of patient stratification for TGF-β inhibitor therapy in HNSCC.
• To re-evaluate TGF-β pathway as a therapeutic target in HNSCC.

Main Methods:

• Review of preclinical studies on TGF-β inhibitors in HNSCC.
• Analysis of completed and ongoing clinical trial data for TGF-β inhibitors in HNSCC.
• Exploration of single-cell transcriptomic data implicating TGF-β signaling.

Main Results:

• Preclinical data show significant anti-tumorigenic potential of TGF-β inhibitors.
• Clinical trials have yielded underwhelming results, indicating challenges in clinical application.
• TGF-β pathway is implicated in HNSCC invasiveness, resistance, and immune evasion.

Conclusions:

• Despite preclinical promise, clinical benefits of TGF-β inhibitors in HNSCC remain elusive.
• Patient stratification may be crucial for realizing the therapeutic potential of TGF-β inhibitors.
• Further research is needed to optimize TGF-β inhibitor strategies for HNSCC treatment.